- Home
- PRAX vs LGND Comparison
PRAX vs LGND Comparison
Compare PRAX & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- LGND
- Stock Information
- Founded
- PRAX 2015
- LGND 1987
- Country
- PRAX United States
- LGND United States
- Employees
- PRAX N/A
- LGND 68
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- PRAX Health Care
- LGND Health Care
- Exchange
- PRAX Nasdaq
- LGND Nasdaq
- Market Cap
- PRAX 4.0B
- LGND 3.2B
- IPO Year
- PRAX 2020
- LGND 1992
- Fundamental
- Price
- PRAX $179.18
- LGND $199.61
- Analyst Decision
- PRAX Strong Buy
- LGND Strong Buy
- Analyst Count
- PRAX 12
- LGND 8
- Target Price
- PRAX $212.42
- LGND $144.71
- AVG Volume (30 Days)
- PRAX 978.5K
- LGND 139.7K
- Earning Date
- PRAX 11-05-2025
- LGND 08-05-2025
- Dividend Yield
- PRAX N/A
- LGND N/A
- EPS Growth
- PRAX N/A
- LGND N/A
- EPS
- PRAX N/A
- LGND N/A
- Revenue
- PRAX $7,463,000.00
- LGND $181,488,000.00
- Revenue This Year
- PRAX N/A
- LGND $18.41
- Revenue Next Year
- PRAX $44.43
- LGND $18.87
- P/E Ratio
- PRAX N/A
- LGND N/A
- Revenue Growth
- PRAX 364.98
- LGND 53.40
- 52 Week Low
- PRAX $26.70
- LGND $81.74
- 52 Week High
- PRAX $206.71
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- PRAX 62.04
- LGND 60.02
- Support Level
- PRAX $159.74
- LGND $201.50
- Resistance Level
- PRAX $188.53
- LGND $212.49
- Average True Range (ATR)
- PRAX 13.41
- LGND 7.90
- MACD
- PRAX -5.00
- LGND 0.75
- Stochastic Oscillator
- PRAX 47.30
- LGND 60.58
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.